Merck Re-Sets Expectations For 2002: Zocor, Prilosec Are Possible Upsides
Executive Summary
Merck's re-calibrated projections for 2002 provide some flexibility for the company if Zocor sales continue to be strong or the launch of generic versions of Prilosec are delayed
You may also be interested in...
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line